Alternative Names: Tesamorelin (GHRH Analog), CJC-1295 (Modified GRF 1-29), Ipamorelin (Synthetic Pentapeptide) Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Studies and Research Data Potential Pituitary Signaling Pathways Research on Tesamorelin and CJC-1295 suggests that they may bind to GHRH receptors, potentially initiating intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase pathways
The standard cycle is 8 to 12 weeks on, followed by 4 to 8 weeks off
As a fragment of growth hormone that specifically targets fat metabolism, it appears to avoid many of the side effects associated with full growth hormone therapy, such as joint pain, fluid retention, and effects on glucose metabolism
HUBERMAN: Rarely, if ever, are we talking about a very targeted and very specific effect of these peptides
Dahabra, MD, and our clinical team